Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI).

Full DD Report for DMPI

You must become a subscriber to view this report.


Recent News from (NASDAQ: DMPI)

DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor
VANCOUVER, British Columbia and MENLO PARK, Calif. , Sept. 4, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the ap...
Source: PR Newswire
Date: September, 04 2018 05:30
DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM
VANCOUVER, British Columbia and MENLO PARK, Calif. , June 26, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today updated patient enrollment data for its Pha...
Source: PR Newswire
Date: June, 26 2018 06:00
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
VANCOUVER, British Columbia and MENLO PARK, Calif. , June 25, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the appointment of Napoleon...
Source: PR Newswire
Date: June, 25 2018 06:00
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for...
Source: SeekingAlpha
Date: June, 16 2018 09:00
DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2018 Results - Earnings Call Transcript
DelMar Pharmaceuticals, Inc. (DMPI) Q3 2018 Earnings Conference Call May 30, 2018 04:30 PM ET Executives Saiid Zarrabian - President and Chief Executive Officer Scott Praill - Chief Financial Officer Dennis Brown - Chief Scientific Officer Analysts Presentation Operato...
Source: SeekingAlpha
Date: May, 30 2018 20:01
Wired News - Keryx Biopharmaceuticals Shares Results of Clinical Trial for Treating Patients with Advanced Chronic Kidney Disease with Ferric Citrate
Stock Monitor: DelMar Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Keryx Biopharma, Inc. (NASDAQ: KERX ) ("Keryx"), all you need to do is sign up now by clicking the following link www.active-investors.com/...
Source: ACCESSWIRE IA
Date: May, 30 2018 07:50
DelMar Appoints Saiid Zarrabian to Full-Time President and CEO
VANCOUVER, British Columbia and MENLO PARK, Calif. , May 22, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (the "Company")(NASDAQ: DMPI) today announced that the board of directors (the "Board") has appointed Saiid Zarrabian as the full-time President and Chief Executive Officer...
Source: PR Newswire
Date: May, 22 2018 05:30
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif. , May, 17, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third ...
Source: PR Newswire
Date: May, 17 2018 05:30
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
VANCOUVER, British Columbia and MENLO PARK, Calif. , April 17, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that ...
Source: PR Newswire
Date: April, 17 2018 14:00
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research
VANCOUVER, British Columbia and MENLO PARK, Calif. , April 16, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced four ...
Source: PR Newswire
Date: April, 16 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.500.45010.500.4501179,197
2018-12-130.46010.4630.510.4533,854
2018-12-120.49990.46010.49990.46112,948
2018-12-110.48470.4946220.500.482356,187
2018-12-100.510.48320.510.482457,991

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-143,23954,0945.9877Cover
2018-12-131,00014,6006.8493Cover
2018-12-1258514,2094.1171Cover
2018-12-102,20214,96314.7163Cover
2018-12-075,20010,18251.0705Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DMPI.


About DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)

Logo for DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)

DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company with a focus on the treatment of cancer.

 

Contact Information

 

 

Current Management

  • Jeffrey Bacha / CEO, President
  • Scott Praill / CFO
  • Dennis Brown / Chief Scientific Officer
  • Jeffrey Bacha / Chairman
  • John Kearns Bell /
  • Dennis Brown /
  • Lynda Cranston /
  • Erich Mohr /
  • Robert Toth /

Current Share Structure

  • Market Cap: $24,997,369 - 03/09/2018
  • Authorized: 50,000,000 - 06/20/2016
  • Issue and Outstanding: 21,927,517 - 02/13/2018

 


Recent Filings from (NASDAQ: DMPI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: May, 17 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 09 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: February, 22 2018

 

 


Daily Technical Chart for (NASDAQ: DMPI)

Daily Technical Chart for (NASDAQ: DMPI)


Stay tuned for daily updates and more on (NASDAQ: DMPI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: DMPI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DMPI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DMPI and does not buy, sell, or trade any shares of DMPI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/